Drugs / RBP-7000
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02768649 | Apr 2011 → Feb 2012 | schizophrenia | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02765555 | Mar → Sep 2010 | schizophrenia | Indivior Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01677377 | Aug 2012 → Apr 2013 | schizophrenia | Indivior Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02203838 | Jun 2014 → Sep 2016 | schizophrenia | Indivior Inc. | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-12-12 | Indivior Inc. | Indivior | Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot indivior.com ↗ |
| 2017-10-02 | Indivior Inc. | Indivior | Indivior Submits New Drug Application to U.S. FDA for RBP-7000 Risperidone Monthly Depot for Treatment of Schizophrenia indivior.com ↗ |
| 2017-03-13 | Indivior Inc. | Indivior | Indivior RBP-7000 Top-line results indivior.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBP-7000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02768649 ↗ |
| Route | Subcutaneous | “120-mg RBP-7000 dose delivered by subcutaneous injection” NCT02203838 ↗ |